Anticoagulation During Pregnancy

Placental Transfer Characteristics

• Heparin compounds, including unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH), do not cross the placenta due to their large molecular size and structure, making them safe for fetal protection 4, 5
• The lack of placental transfer of heparin compounds means these medications cannot cause fetal bleeding or direct teratogenic effects 2, 3
• In contrast, warfarin and other vitamin K antagonists do cross the placenta and can cause embryopathy, CNS abnormalities, and fetal hemorrhage 6, 4

Safety Profile for the Fetus

• The American College of Cardiology/American Heart Association (ACC/AHA) consistently confirms that heparin compounds are safe for the fetus 1, 2, 3
• While heparin compounds don't cross the placenta, bleeding at the uteroplacental junction remains a theoretical concern 5, 7

Clinical Implications

• For pregnant women requiring anticoagulation, heparin compounds are preferred over vitamin K antagonists during the first trimester and near delivery 4, 9
• When switching from warfarin to heparin compounds during pregnancy planning, frequent pregnancy tests should be performed to ensure timely transition 10, 9
• Dosing of LMWH requires adjustment as pregnancy progresses due to changes in volume of distribution, with monitoring of anti-Xa levels recommended 4, 5

Important Caveats

• The established consensus across multiple guidelines remains that heparin compounds do not cross the placenta and are safe for the fetus 1, 2, 5
• The 2018 CHEST guidelines for antithrombotic therapy in atrial fibrillation note that LMWH can be safely used during pregnancy when anticoagulation is required 8